Annexin Pharmaceuticals AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was SEK 40.73 million compared to SEK 52.14 million a year ago. Basic loss per share from continuing operations was SEK 0.28 compared to SEK 0.64 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.297 SEK | +2.41% | +10.00% | +14.23% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.23% | 9.39M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ANNX Stock
- News Annexin Pharmaceuticals AB
- Annexin Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022